{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG-013736+%28AXITINIB%29&page=2",
    "query": {
      "intervention": "AG-013736 (AXITINIB)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 112,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG-013736+%28AXITINIB%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG-013736+%28AXITINIB%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T05:45:18.408Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00076024",
      "title": "AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "AG-013736 (axitinib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 174,
      "start_date": "2004-02",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2012-06-26",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • Berkeley, California • Montebello, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Montebello",
          "state": "California"
        },
        {
          "city": "Monterey Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076024"
    },
    {
      "nct_id": "NCT04693468",
      "title": "Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Recurrent Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib Isethionate",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2020-12-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04693468"
    },
    {
      "nct_id": "NCT02636725",
      "title": "Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alveolar Soft Part Sarcoma",
        "Soft Tissue Sarcomas"
      ],
      "interventions": [
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonathan Trent, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2016-04-19",
      "completion_date": "2023-03-03",
      "has_results": true,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02636725"
    },
    {
      "nct_id": "NCT03438708",
      "title": "Prior Axitinib as a Determinant of Outcome of Renal Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Axitinib Oral Tablet [Inlyta]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2018-03-05",
      "completion_date": "2026-03-04",
      "has_results": false,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • Cleveland, Ohio",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03438708"
    },
    {
      "nct_id": "NCT00678392",
      "title": "Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Neoplasms"
      ],
      "interventions": [
        {
          "name": "Axitinib (AG-013736)",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 723,
      "start_date": "2008-09-03",
      "completion_date": "2016-02-25",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 161,
      "location_summary": "Burbank, California • Downey, California • Glendale, California + 103 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00678392"
    },
    {
      "nct_id": "NCT07227415",
      "title": "Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell",
        "Advanced Renal Cell Carcinoma",
        "Renal Cancer",
        "Renal Neoplasm",
        "Clear Cell Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Clear-cell Metastatic Renal Cell Carcinoma",
        "Carcinoma, Renal Cell Metastasis",
        "Advanced or Metastatic Renal Cell Carcinoma",
        "Carcinoma, Renal Cell, Advanced",
        "Metastatic Renal Cell Cancer",
        "Metastatic Renal Cell Carcinoma ( mRCC)",
        "Metastatic/Advanced Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-08634404",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Casdatifan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2026-02-10",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 140,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 84 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227415"
    },
    {
      "nct_id": "NCT00920816",
      "title": "Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Neoplasms"
      ],
      "interventions": [
        {
          "name": "Axitinib (AG-013736)",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 492,
      "start_date": "2009-08-25",
      "completion_date": "2021-04-29",
      "has_results": true,
      "last_update_posted_date": "2022-05-06",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 58,
      "location_summary": "Miami, Florida • Arlington Heights, Illinois • Niles, Illinois + 39 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "Niles",
          "state": "Illinois"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920816"
    },
    {
      "nct_id": "NCT04989699",
      "title": "Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OTX-TKI/Sham",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept/Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-07-28",
      "completion_date": "2023-12-18",
      "has_results": false,
      "last_update_posted_date": "2024-01-26",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 6,
      "location_summary": "Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04989699"
    },
    {
      "nct_id": "NCT00076011",
      "title": "Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Neoplasms"
      ],
      "interventions": [
        {
          "name": "Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2003-10",
      "completion_date": "2007-02",
      "has_results": true,
      "last_update_posted_date": "2012-06-26",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076011"
    },
    {
      "nct_id": "NCT02187302",
      "title": "CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "CRLX101",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (Investigator Choice)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewLink Genetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2014-07",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-10-01T05:45:18.408Z",
      "location_count": 38,
      "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 33 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02187302"
    }
  ]
}